Protagonist Therapeutics Inc. (PTGX)

12.01
0.02 0.17
NASDAQ : Health Technology
Prev Close 11.99
Open 12.00
Day Low/High 11.88 / 12.42
52 Wk Low/High 5.49 / 16.67
Volume 86.07K
Avg Volume 194.40K
Exchange NASDAQ
Shares Outstanding 26.28M
Market Cap 304.59M
EPS -1.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Protagonist Therapeutics Reports Granting Of Inducement Awards

Protagonist Therapeutics Reports Granting Of Inducement Awards

NEWARK, Calif., Sept.

Protagonist Therapeutics Reports Second Quarter 2019 Financial Results

Protagonist Therapeutics Reports Second Quarter 2019 Financial Results

-- Preliminary Phase 2 results for hepcidin mimetic PTG-300 in beta-thalassemia are expected in the fourth quarter of 2019 --

Protagonist Therapeutics Breaks Below 200-Day Moving Average - Notable For PTGX

Protagonist Therapeutics Breaks Below 200-Day Moving Average - Notable For PTGX

In trading on Tuesday, shares of Protagonist Therapeutics Inc crossed below their 200 day moving average of $9.64, changing hands as low as $8.26 per share. Protagonist Therapeutics Inc shares are currently trading off about 1.7% on the day.

Oversold Conditions For Protagonist Therapeutics (PTGX)

Oversold Conditions For Protagonist Therapeutics (PTGX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Sustained Dose-Related Target Engagement Activity In A Multiple Ascending Dose Phase 1 Study

Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Sustained Dose-Related Target Engagement Activity In A Multiple Ascending Dose Phase 1 Study

-- PN-943 is safe and well tolerated with gut-restricted exposure; Phase 2 ulcerative colitis study initiation planned for early 2020 --

Protagonist Therapeutics Reports Granting Of Inducement Award

Protagonist Therapeutics Reports Granting Of Inducement Award

NEWARK, Calif., July 16, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc.

Protagonist Therapeutics Reports Granting Of Inducement Award

Protagonist Therapeutics Reports Granting Of Inducement Award

NEWARK, Calif., June 18, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc.

Protagonist Therapeutics To Present At The BMO 2019 Prescription For Success Healthcare Conference

Protagonist Therapeutics To Present At The BMO 2019 Prescription For Success Healthcare Conference

NEWARK, Calif., June 17, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc.

Protagonist Therapeutics Reports Granting Of Inducement Award

Protagonist Therapeutics Reports Granting Of Inducement Award

NEWARK, Calif., June 4, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc.

Protagonist Therapeutics Appoints Don Kalkofen As Chief Financial Officer

Protagonist Therapeutics Appoints Don Kalkofen As Chief Financial Officer

NEWARK, Calif., May 29, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc.

Protagonist Therapeutics Reports First Quarter 2019 Financial Results

Protagonist Therapeutics Reports First Quarter 2019 Financial Results

-- PTG-200 collaboration agreement with Janssen Biotech expanded to include second generation oral IL-23 receptor antagonists; expanded agreement triggers $25 million milestone payment to Protagonist --

RSI Alert: Protagonist Therapeutics (PTGX) Now Oversold

RSI Alert: Protagonist Therapeutics (PTGX) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Protagonist Therapeutics To Present Preclinical Data On PN-943 At Digestive Disease Week Conference 2019

Protagonist Therapeutics To Present Preclinical Data On PN-943 At Digestive Disease Week Conference 2019

-- Oral plenary presentation to detail properties of oral, gut-restricted alpha-4-beta-7 integrin antagonist candidate PN-943 --

Protagonist Therapeutics Enters Oversold Territory (PTGX)

Protagonist Therapeutics Enters Oversold Territory (PTGX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ALK, ARCO, BIOS, CRD.A, DCO, GNE, KEYW, LOGM, OUT, SIGA, TBBK, TGP, TPIC, XXII Downgrades: ADS, BYD, CCS, ENTA, HL, ICBK, MTW, XOMA Initiations: BPMP, PTGX Read on to get TheStreet Quant Ratings' detailed report:

Oversold Conditions For Protagonist Therapeutics (PTGX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Oversold Conditions For Protagonist Therapeutics (PTGX)

Oversold Conditions For Protagonist Therapeutics (PTGX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Protagonist Therapeutics Inks License Pact With Johnson & Johnson's Janssen

Protagonist Therapeutics Inks License Pact With Johnson & Johnson's Janssen

The license and collaboration deal for Protagonist's PTG-200 is worth up to to $990M plus royalties.

Protagonist Therapeutics Becomes Oversold (PTGX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Protagonist Therapeutics is Now Oversold (PTGX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Protagonist Therapeutics is Now Oversold (PTGX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Oversold Conditions For Protagonist Therapeutics (PTGX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

TheStreet Quant Rating: D (Sell)